The Patch Forward Prize will award up to $50 million in prizes. The competition awarded four Concept Stage winners $2 million each. In the upcoming Preclinical Stage, up to three winners will each receive a $7 million Preclinical Stage award. In the Clinical Stage, up to two winners will each receive a $10.5 million Clinical Stage award.
Winners
Concept Stage winners
The Patch Forward Prize awarded four Concept Stage teams $2 million each for their submissions detailing a development plan to advance a safe, tolerable, and immunogenic patch-based RNA vaccine. The competition received more than 30 Concept Stage submissions from around the world, representing both new and established patch developers, RNA vaccine developers, and research teams from academic institutions.
LTS Lohmann, partnered with BioNet
A next-generation microneedle patch-based mRNA vaccine targeting seasonal influenza viruses, with the flexibility to pivot to pandemic influenza strains.
For more information on this team, please contact May Pidding at .
Micron Biomedical, partnered with Zipcode Bio
Co-developing mRNA-based, broadly protecting influenza vaccines based on dissolvable microarrays and delivered without an injection.
For more information on this team, please contact Sebastien Henry at .
PopVax, partnered with LTS Lohmann
A seasonal influenza vaccine built on a novel mRNA-encoded immunogen display architecture delivered via a dissolvable microarray patch.
For more information on this team, please contact Darshit Mehta at .
Vaxxas, partnered with The University of Queensland BASE
A high-density microarray patch-based mRNA vaccine for COVID-19 designed for enhanced immunity.
For more information on this team, please contact .